| Personalized medicine: a paradigm for a sustainable pharmaceutical industry? | |
| | |
MedLine Citation:
|
PMID: 19562640 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Personalized medicine is a custom-tailored approach to patient treatment based on individual genetic traits. In personalized medicine, a patient group is characterized by a clinical biomarker that has been correlated to a differential response to drug treatment. During the past decade, several developments in the understanding of the structure and function of the human genome have occurred that bring personalized medicine closer to becoming a reality. The promise of personalized medicine lies in a clinical biomarker-driven patient stratification, and focused smaller-sized clinical trials that result in a shorter development time and reduced overall development cost. Personalized medicine has the potential to offer a new business model for the pharmaceutical industry by providing a more efficient drug discovery process with reduced cost. |
| | |
Authors:
|
Samuel Chackalamannil; Manoj C Desai |
Publication Detail:
|
Type: Editorial |
Journal Detail:
|
Title: Current opinion in drug discovery & development Volume: 12 ISSN: 2040-3437 ISO Abbreviation: Curr Opin Drug Discov Devel Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-29 Completed Date: 2010-01-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100887519 Medline TA: Curr Opin Drug Discov Devel Country: England |
Other Details:
|
Languages: eng Pagination: 443-5 Citation Subset: IM |
Affiliation:
|
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Drug Discovery* Drug Industry / methods* Individualized Medicine / methods* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymp...
Next Document: Recent progress in the discovery and development of negative allosteric modulators of mGluR5.